Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database

Abstract Background Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas with poor prognosis, particularly in patients with relapsed or refractory (R/R) disease. Romidepsin and tucidinostat are histone deacetylase inhibitors used to treat R/R PTCL. No head-to-head post-marketing s...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Nao Takatsu, Jun Matsumoto, Yurie Oka, Tomonori Sakai, Naohiro Iwata, Tsukasa Higashionna, Tatsuaki Takeda, Hirofumi Hamano, Yoshito Zamami
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-03-01
Serija:	Journal of Pharmaceutical Health Care and Sciences
Teme:	Romidepsin Tucidinostat Adverse event JADER Pharmacovigilance
Online dostop:	https://doi.org/10.1186/s40780-026-00565-3
Oznake:	Označite Brez oznak, prvi označite!